Hyloris Buys Out Maxigesic IV Royalty Rights From Alter Pharma
As Both Companies Sign A €5.75m Renegotiated License Agreement
Belgian value-added medicines specialist Hyloris Pharmaceuticals has renegotiated its licensing agreement with Alter Pharma group, wrapping up all previous agreements. Under the new agreement, Hyloris will forego all past commitments and all further future royalty obligations to Alter for Maxigesic IV.
